Maury Raycroft (analyst) Hi everyone, my name is Maury Raycroft, and I am one of the biotech analysts at Jefferies. Thanks for joining us for our London conference. And I would like to welcome the … [Read more...] about BCRX Transcript: Jefferies London Conference 2021
Novartis
An Update on RegenXBio
Previously, our Chief Operating Officer Sultan Beardsley outlined an investment thesis for RegenXBio. This detailed report can be read here: Could This Biotech Stock Get Bought For $5.5 Billion? … [Read more...] about An Update on RegenXBio
Gene therapy treatment for SMA approved! (Full TA)
Gene Therapy for SMA-- Full technical analysis #VolatilityWatch by follow_the_money on TradingView.com RegenexBio (RGNX) and Novartis (NVS) just received FDA approval of Gene Therapy treatment for … [Read more...] about Gene therapy treatment for SMA approved! (Full TA)
ASCO Alert: Stay Ahead of the Updates
One of the most heralded oncology conferences is the annual American Society of Clinical Oncologists (ASCO). This year, Chicago is hosting the annual conference, which is running from May 31st through … [Read more...] about ASCO Alert: Stay Ahead of the Updates
Technically Swinging CNAT
Swing Thesis This swing-trade for Conatus Pharmaceuticals, (Nasdaq: CNAT) is based on Technical Analysis (which aligns with some key dates) and a fundamental component. With regards to technical … [Read more...] about Technically Swinging CNAT
Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market
Introduction Bristol-Myers Squibb (NYSE: BMY) is a profitable global bio-pharmaceutical company targeting an array of serious diseases and unmet medical needs. Earlier this month BMY announced … [Read more...] about Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market
MS Morning Update-1/08/2019
NVS receives Breakthrough Therapy Designation (BTD) for crizanlizumab (SEG101) for the prevention of vaso-occlusive crises in sickle cell disease Crizanlizumab is under development as a monthly … [Read more...] about MS Morning Update-1/08/2019
Post-ENCORE-PH Interview With CNAT
Leave a comment and click here to sub for MS article alerts and our newsletter On the heels of the contentious revealing of ENCORE-PH top-line data MS Money Moves decided to go to the source for … [Read more...] about Post-ENCORE-PH Interview With CNAT
A Closer Look At CNAT’s “Failed” Clinical Study
Introduction Conatus Pharmaceuticals (Nasdaq: CNAT) recently released highly anticipated top-line data from their Encore-PH clinical trial. The study investigated the efficacy and safety of … [Read more...] about A Closer Look At CNAT’s “Failed” Clinical Study
Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
You must be logged in to post a comment.